Merit Medical Systems Inc

Merit Medical Systems Inc(MMSI)の株式分析

$90.490

+0.959 (+1.06%)終値時点

Loading chart…
High
90.720
Open
89.960
VWAP
90.16
Vol
341.63K
Mkt Cap
4.85B
Low
89.275
Amount
30.80M
EV/EBITDA, TTM
14.78

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.

www.merit.com

AI analysis of Merit Medical Systems Inc (MMSI)

buy

Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a Q2 revenue of $418.8 million, which is a 9.5% year-over-year increase, and a non-GAAP EPS of $1.19, exceeding expectations by $0.23. Additionally, the forward P/E ratio of 21.88 suggests potential for growth compared to its current price of $90.49. However, the main risk is the current RSI of 55.45, indicating that the stock is nearing overbought territory.

Analyst Ratings (9)

+15.63% upside
Buy
8 Buy
1 Hold
0 Sell
Current: 90.49
安値
90.00
平均
104.63
高値
122.00

BofA

2026-08-12

目標株価

$97

Neutral

Canaccord

2026-08-03

目標株価

$94

Buy

BTIG

2026-07-31

目標株価

$105

Buy

Raymond James

2026-07-31

目標株価

$100

Outperform

Barrington

2026-07-31

目標株価

$114

Outperform

バリュエーション指標

The current forward P/E ratio for Merit Medical Systems Inc (MMSI) is 21.88, compared to its 5-year average forward P/E of 24.51.

Forward P/E

Fair
5Y Average P/E
24.51
Current P/E
21.88
割高
28.06
割安
20.95

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
17.01
Current EV/EBITDA
14.78
割高
19.24
割安
14.77

Forward P/S

Fair
5Y Average P/S
3.29
Current P/S
3.08
割高
3.77
割安
2.80

Alphio AI Price Scenarios for MMSI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MMSI

$115.59

シナリオ価格

B

Base

Base · 50%MMSI

$110.74

シナリオ価格

B

Bear

Bear · 25%MMSI

$87.37

シナリオ価格

Whales holding MMSI

G

Greenhouse Funds LLLP

+ HoldingMMSI

+9.14%

3M Return

M

Maverick Capital, Ltd.

+ HoldingMMSI

+4.67%

3M Return

イベントタイムライン

2026-07-30 (ET)

20:30:00

Amazon Earnings Beat Expectations, Stock Rises Nearly 10%

16:30:00

Merit Raises FY26 Revenue Outlook to $1.631B-$1.643B

2026-04-30 (ET)

16:21:00

Company Narrows FY26 Revenue View to $1.612B-$1.634B

16:21:00

Merit Q1 Revenue Exceeds Expectations at $381.9M

ニュース

MMSI FAQ — answered by Alphio AI

Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a Q2 revenue of $418.8 million, which is a 9.5% year-over-year increase, and a non-GAAP EPS of $1.19, exceeding expectations by $0.23. Additionally, the forward P/E ratio of 21.88 suggests potential for growth compared to its current price of $90.49. However, the main risk is the current RSI of 55.45, indicating that the stock is nearing overbought territory.

9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める